|
Gene: DISP2 |
Gene summary for DISP2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | DISP2 | Gene ID | 85455 |
Gene name | dispatched RND transporter family member 2 | |
Gene Alias | C15orf36 | |
Cytomap | 15q15.1 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | A7MBM2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
85455 | DISP2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.37e-11 | 4.01e-01 | -0.1808 |
85455 | DISP2 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.70e-02 | 1.44e-01 | -0.1088 |
85455 | DISP2 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.76e-02 | 1.01e-01 | -0.1954 |
85455 | DISP2 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.40e-05 | 3.50e-01 | -0.1464 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DISP2 | SNV | Missense_Mutation | novel | c.2941N>A | p.Leu981Met | p.L981M | A7MBM2 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
DISP2 | SNV | Missense_Mutation | novel | c.2942N>G | p.Leu981Arg | p.L981R | A7MBM2 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
DISP2 | SNV | Missense_Mutation | novel | c.161G>C | p.Arg54Thr | p.R54T | A7MBM2 | protein_coding | deleterious_low_confidence(0.03) | benign(0.019) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DISP2 | SNV | Missense_Mutation | novel | c.825G>T | p.Glu275Asp | p.E275D | A7MBM2 | protein_coding | tolerated(1) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DISP2 | SNV | Missense_Mutation | c.3631N>G | p.Pro1211Ala | p.P1211A | A7MBM2 | protein_coding | tolerated(0.34) | benign(0.121) | TCGA-C8-A12K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
DISP2 | SNV | Missense_Mutation | c.3239C>T | p.Ala1080Val | p.A1080V | A7MBM2 | protein_coding | deleterious(0) | possibly_damaging(0.891) | TCGA-GM-A2DF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
DISP2 | SNV | Missense_Mutation | rs143054067 | c.950N>A | p.Arg317His | p.R317H | A7MBM2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DISP2 | SNV | Missense_Mutation | novel | c.2827N>T | p.Arg943Cys | p.R943C | A7MBM2 | protein_coding | deleterious(0.05) | benign(0.007) | TCGA-C5-A7CG-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
DISP2 | SNV | Missense_Mutation | c.540N>G | p.Ile180Met | p.I180M | A7MBM2 | protein_coding | deleterious(0.02) | benign(0.295) | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
DISP2 | SNV | Missense_Mutation | rs201542979 | c.1106N>A | p.Arg369Gln | p.R369Q | A7MBM2 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-EA-A3HQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |